PriceTargets.com logo

Aurora Cannabis - ACB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.34 As of 11/14/2024 01:00 AM ET
▼ -0.2 (-4.41%)

This chart shows the closing price for ACB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aurora Cannabis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Aurora Cannabis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.34.

This chart shows the closing price for ACB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Aurora Cannabis. This rating has held steady since September 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/9/2024Canaccord Genuity GroupUpgradeHold ➝ Buy
2/13/2023CIBCLower TargetC$22.50 ➝ C$17.50
1/27/2023Stifel NicolausLower TargetC$17.50 ➝ C$14.50
12/28/2022Piper SandlerLower Target$20.00 ➝ $10.00
9/22/2022Atb Cap MarketsUpgradeUnderperform ➝ Sector Perform
9/21/2022Canaccord Genuity GroupUpgradeSell ➝ Hold
9/21/2022Piper SandlerLower TargetNeutral$40.00 ➝ $30.00
6/24/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight
6/6/2022Stifel NicolausUpgradeSell ➝ Hold$21.50
5/16/2022CIBCLower TargetC$65.00 ➝ C$37.50
5/13/2022Cantor FitzgeraldLower TargetC$76.00 ➝ C$39.00
2/11/2022Cantor FitzgeraldLower TargetC$107.50 ➝ C$76.00
2/3/2022CIBCLower TargetC$92.50 ➝ C$65.00
11/10/2021CIBCUpgradeUnderperform ➝ Neutral
10/1/2021Jefferies Financial GroupReiterated RatingHold
9/29/2021CIBCLower TargetUnderperformC$70.00 ➝ C$65.00
9/28/2021Piper SandlerReiterated RatingHold$70.00
9/28/2021MKM PartnersUpgradeSell ➝ Neutral$60.00 ➝ $70.00
9/28/2021Needham & Company LLCReiterated RatingSell
9/23/2021CIBCLower TargetUnderperformC$80.00 ➝ C$70.00
9/17/2021Cantor FitzgeraldLower TargetNeutralC$120.00 ➝ C$83.00
9/3/2021Jefferies Financial GroupUpgradeUnderperform ➝ Hold$74.90 ➝ $67.80
7/23/2021Atb Cap MarketsReiterated RatingUnderperform
5/17/2021CIBCLower TargetNeutral ➝ UnderperformerC$150.00 ➝ C$90.00
5/14/2021Needham & Company LLCInitiated CoverageSell
5/14/2021Cantor FitzgeraldLower TargetNeutral$112.50 ➝ $90.00
5/14/2021BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$90.00 ➝ $80.00
5/11/2021CIBCDowngradeNeutral ➝ Sector Underperform$150.00 ➝ $90.00
4/28/2021Bank of AmericaInitiated CoverageNeutral
4/5/2021CIBCLower TargetNeutral$185.00 ➝ $150.00
2/16/2021CIBCBoost TargetNeutral$170.00 ➝ $185.00
2/12/2021MKM PartnersDowngradeNeutral ➝ Sell
2/12/2021Needham & Company LLCDowngradeHold ➝ Underperform
2/12/2021Cantor FitzgeraldBoost TargetNeutral$170.00 ➝ $180.00
2/12/2021DesjardinsDowngradeHold ➝ Sell
2/8/2021CIBCBoost TargetNeutral$150.00 ➝ $170.00
2/5/2021Cantor FitzgeraldBoost TargetNeutral$160.00 ➝ $170.00
1/25/2021Cantor FitzgeraldBoost TargetNeutral$120.00 ➝ $160.00
1/4/2021Jefferies Financial GroupReiterated RatingUnderperform$45.90
12/17/2020BMO Capital MarketsDowngradeMarket Perform ➝ Underperform$90.00
11/16/2020Atb Cap MarketsUpgradeUnderperform ➝ Sector Perform
11/16/2020Jefferies Financial GroupDowngradeHold ➝ Underperform$55.60 ➝ $37.50
11/11/2020Stifel NicolausDowngradeHold ➝ Sell
11/10/2020CIBCBoost TargetNeutral$120.00 ➝ $150.00
11/9/2020Atb Cap MarketsDowngradeSector Perform ➝ Underperform
11/9/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$130.00 ➝ $120.00
10/28/2020Stifel NicolausLower TargetHold$105.00 ➝ $36.00
10/27/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$180.00 ➝ $70.00
9/24/2020CIBCLower TargetNeutral$200.00 ➝ $120.00
9/23/2020CowenReiterated RatingHold$100.00
9/23/2020Cantor FitzgeraldBoost TargetOverweight$175.00 ➝ $180.00
9/23/2020Needham & Company LLCReiterated RatingHold
9/23/2020Piper SandlerLower TargetNeutral$100.00 ➝ $80.00
9/21/2020Jefferies Financial GroupUpgradeUnderperform ➝ Hold
9/9/2020Stifel NicolausLower TargetPositive ➝ Hold$160.00 ➝ $105.00
9/9/2020Cantor FitzgeraldLower TargetOverweight$290.00 ➝ $175.00
9/8/2020Needham & Company LLCReiterated RatingHold
9/8/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$90.00
8/18/2020CIBCLower TargetNeutral$240.00 ➝ $200.00
6/24/2020Cantor FitzgeraldBoost TargetOverweight$270.00 ➝ $290.00
6/24/2020Stifel NicolausUpgradeSell ➝ Hold$62.00 ➝ $175.00
6/23/2020Needham & Company LLCInitiated CoverageHold
5/22/2020CIBCBoost TargetNeutral$140.00 ➝ $240.00
5/22/2020Jefferies Financial GroupDowngradeHold ➝ Underperform$120.00 ➝ $140.00
5/21/2020Cantor FitzgeraldBoost TargetMarket Perform ➝ Overweight$220.00 ➝ $270.00
5/19/2020MKM PartnersInitiated CoverageHold$180.00
5/18/2020CIBCReiterated RatingBuy ➝ Market Perform$270.00 ➝ $140.00
5/15/2020Pi FinancialReiterated RatingNeutral
5/15/2020DesjardinsUpgradeBuy
5/15/2020Piper SandlerUpgradeUnderweight ➝ Neutral$120.00 ➝ $100.00
5/13/2020Cantor FitzgeraldBoost TargetOverweight$220.00
5/12/2020Eight CapitalReiterated RatingHold$110.00
4/13/2020Cantor FitzgeraldLower TargetOverweight$456.00 ➝ $330.00
4/13/2020Needham & Company LLCReiterated RatingHold
2/27/2020Bryan, Garnier & CoDowngradeNeutral ➝ Sell
2/25/2020Needham & Company LLCInitiated CoverageHold$180.00
2/24/2020Cantor FitzgeraldBoost TargetOverweight$450.00 ➝ $456.00
2/24/2020CowenDowngradeOutperform ➝ Market Perform$720.00 ➝ $300.00
2/16/2020Pi FinancialReiterated RatingHold$240.00
2/16/2020CIBCReiterated RatingHold$270.00
2/14/2020MKM PartnersUpgradeSell ➝ Neutral
2/10/2020CIBCReiterated RatingHold$300.00
2/7/2020Pi FinancialDowngradeHold$240.00
2/7/2020Eight CapitalDowngradeBuy ➝ Neutral
2/7/2020Cantor FitzgeraldLower TargetOverweight$600.00 ➝ $450.00
2/7/2020Compass PointLower TargetNeutral$600.00 ➝ $240.00
2/6/2020Jefferies Financial GroupDowngradeHold
1/10/2020Piper Sandler CompaniesDowngradeNeutral ➝ Underweight$360.00 ➝ $120.00
1/10/2020Bank of AmericaDowngradeNeutral ➝ Underperform$120.00
1/10/2020Piper SandlerDowngradeOverweight ➝ Neutral$360.00 ➝ $120.00
12/31/2019Jefferies Financial GroupDowngradeHold$360.00
12/23/2019MKM PartnersReiterated RatingSell$360.00 ➝ $240.00
12/23/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$360.00
11/26/2019Cantor FitzgeraldReiterated RatingBuy$528.00
11/15/2019MKM PartnersDowngradeHold$420.00 ➝ $360.00
11/15/2019Cantor FitzgeraldUpgradeNeutral ➝ Overweight$612.00 ➝ $702.00
11/15/2019Piper Sandler CompaniesLower TargetNeutral$480.00 ➝ $360.00
(Data available from 11/15/2019 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024
  • 13 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2024
  • 4 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Aurora Cannabis logo
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Read More

Today's Range

Now: $4.34
Low: $4.34
High: $4.53

50 Day Range

MA: $5.54
Low: $4.34
High: $6.11

52 Week Range

Now: $4.34
Low: $2.84
High: $9.35

Volume

1,016,356 shs

Average Volume

3,059,511 shs

Market Capitalization

$238.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurora Cannabis?

The following Wall Street analysts have issued research reports on Aurora Cannabis in the last twelve months: Canaccord Genuity Group Inc..
View the latest analyst ratings for ACB.

What is the current price target for Aurora Cannabis?

0 Wall Street analysts have set twelve-month price targets for Aurora Cannabis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aurora Cannabis in the next year.
View the latest price targets for ACB.

What is the current consensus analyst rating for Aurora Cannabis?

Aurora Cannabis currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACB will outperform the market and that investors should add to their positions of Aurora Cannabis.
View the latest ratings for ACB.

What other companies compete with Aurora Cannabis?

Other companies that are similar to Aurora Cannabis include Mesoblast, Collegium Pharmaceutical, 89bio, CARGO Therapeutics and Phathom Pharmaceuticals. Learn More about companies similar to Aurora Cannabis.

How do I contact Aurora Cannabis' investor relations team?

Aurora Cannabis' physical mailing address is 10355 JASPER AVENUE SUITE 500, EDMONTON A0, T5J 1Y6. The company's listed phone number is (855) 279-4652 and its investor relations email address is [email protected]. The official website for Aurora Cannabis is auroramj.com. Learn More about contacing Aurora Cannabis investor relations.